Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics

NCT03376763 is registered in ClinicalTrials.gov with Korea Otsuka Pharmaceutical Co., Ltd. as lead sponsor.

NCT NCT03376763
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03376763 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
MAintain the Efficacy and Safety in Treatment of Schizophrenia After Switching to Long-acTing Injectable aRipiprazole From Oral Atypical Antipsychotics
Lead sponsor
Korea Otsuka Pharmaceutical Co., Ltd.
Phase
Phase 4
Overall status
Completed
Start date
November 21, 2017
Completion date
November 19, 2021
Enrollment
201 (actual)
Sites
27

Conditions

As the registry lists them; a condition with its own page is linked.

antipsychotics, aripiprazole, lai, long-acting injection, schizophrenia